Wikidata

(Q65364104)

English

Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF

clinical trial

In more languages
default for all languages
No label defined

No description defined

Statements

short name
RELAX-AHF-2 (English)
0 references
title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients (English)
0 references
sponsor
Novartis
0 references
country
Argentina
0 references
Australia
0 references
Austria
0 references
Belgium
0 references
Brazil
0 references
Bulgaria
0 references
Canada
0 references
Chile
0 references
Colombia
0 references
Denmark
0 references
France
0 references
Germany
0 references
Greece
0 references
Hungary
0 references
Ireland
0 references
Israel
0 references
Italy
0 references
Mexico
0 references
Netherlands
0 references
Norway
0 references
Peru
0 references
Poland
0 references
Portugal
0 references
Romania
0 references
Slovakia
0 references
South Africa
0 references
Spain
0 references
Sweden
0 references
Switzerland
0 references
Turkey
0 references
United Kingdom
0 references
start time
2 October 2013
0 references
end time
23 January 2017
0 references
number of participants
6,600
0 references
research site
Novartis
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q65364104&oldid=2237278328"